Foster NEXThaler or MDI inhaler (Beclometasone/Formoterol)

Foster is a widely recognized medical treatment used for the management of asthma and chronic obstructive pulmonary disease (COPD). It is a combination therapy containing beclometasone dipropionate and formoterol fumarate dihydrate. The product is most commonly distributed in two forms: a pressurized metered-dose inhaler (pMDI) and the NEXThaler, which is a dry powder inhaler.

The brand was developed by Chiesi Farmaceutici S.p.A., a global pharmaceutical company based in Italy. Chiesi is known for its strong focus on respiratory health and continues to manufacture the product primarily out of its advanced facilities in Italy and France to serve global markets. The brand remains under the private ownership of the Chiesi family, maintaining its status as one of the largest independent pharmaceutical groups in Europe.